organization · Reporting owner
Havencrest Healthcare Partners GP, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Starling Oncology, Inc.
Report date August 16, 2024 · Filed August 20, 2024
Jointly reported with Havencrest Healthcare Partners, L.P., TOI HC I, LLC
Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | IndirectSee footnote | 7,884,044 |
Reported balance
After 2024-08-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-08-16 · Other · Disposed 8,701,823 · Balance 7,884,044 F1: On August 16, 2024, TOI HC I, LLC distributed an aggregate of 8,701,823 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC 1 Distribution"). Immediately following the TOI HC 1 Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 7,631,418 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. |
| Common stockSEC Table I · non-derivative | IndirectSee footnote | 252,626 |
Reported balance
After 2024-08-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-08-16 · Other · Disposed 7,631,418 · Balance 252,626 F2: Also on August 16, 2024, following the TOI HC 1 Distribution, Havencrest Healthcare Partners, L.P. made a further pro-rata in-kind distribution of the 7,631,418 shares it received in the TOI HC 1 Distribution to its limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 152,626 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 16, 2024, TOI HC I, LLC distributed an aggregate of 8,701,823 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC 1 Distribution"). Immediately following the TOI HC 1 Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 7,631,418 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.
F2: Also on August 16, 2024, following the TOI HC 1 Distribution, Havencrest Healthcare Partners, L.P. made a further pro-rata in-kind distribution of the 7,631,418 shares it received in the TOI HC 1 Distribution to its limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 152,626 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2024 Filed Aug 20, 2024 10:15 UTC | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon stock | 7,631,418 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-098843 · ownership.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 252,626 F2 · kind: Also on August 16, 2024, following the TOI HC 1 Distribution, Havencrest Healthcare Partners, L.P. made a further pro-rata in-kind distribution of the 7,631,418 shares it received in the TOI HC 1 Distribution to its limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 152,626 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. F2 · price: Also on August 16, 2024, following the TOI HC 1 Distribution, Havencrest Healthcare Partners, L.P. made a further pro-rata in-kind distribution of the 7,631,418 shares it received in the TOI HC 1 Distribution to its limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 152,626 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. F2 · ownership.nature: Also on August 16, 2024, following the TOI HC 1 Distribution, Havencrest Healthcare Partners, L.P. made a further pro-rata in-kind distribution of the 7,631,418 shares it received in the TOI HC 1 Distribution to its limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 152,626 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 10:15 UTC | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon stock | 8,701,823 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-098843 · ownership.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,884,044 F1 · kind: On August 16, 2024, TOI HC I, LLC distributed an aggregate of 8,701,823 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC 1 Distribution"). Immediately following the TOI HC 1 Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 7,631,418 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. F1 · price: On August 16, 2024, TOI HC I, LLC distributed an aggregate of 8,701,823 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC 1 Distribution"). Immediately following the TOI HC 1 Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 7,631,418 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. F1 · ownership.nature: On August 16, 2024, TOI HC I, LLC distributed an aggregate of 8,701,823 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC 1 Distribution"). Immediately following the TOI HC 1 Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 7,631,418 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 00:07 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 8,637 | $2.12 | $18,310.44 |
DisclosureSEC source: 0000950170-24-009050 · ownership.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.19, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:19 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 6,979 | $2.14 | $14,935.06 |
DisclosureSEC source: 0000899243-24-000121 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,637 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.09 to $2.19, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock. Read SEC document |
| January 25, 2024 Filed Jan 27, 2024 00:19 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 11,882 | $2.07 | $24,595.74 |
DisclosureSEC source: 0000899243-24-000121 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 15,616 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.01 to $2.19, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock. Read SEC document |
| January 24, 2024 Filed Jan 27, 2024 00:19 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 24,915 | $2.30 | $57,304.50 |
DisclosureSEC source: 0000899243-24-000121 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 27,498 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.15 to $2.44, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:02 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 5,338 | $2.11 | $11,263.18 |
DisclosureSEC source: 0000899243-24-000108 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 52,413 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.08 to $2.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 01:02 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 10,263 | $2.12 | $21,757.56 |
DisclosureSEC source: 0000899243-24-000108 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 57,751 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.08 to $2.19, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock. Read SEC document |
| January 19, 2024 Filed Jan 24, 2024 01:02 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 11,986 | $2.13 | $25,530.18 |
DisclosureSEC source: 0000899243-24-000108 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 68,014 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.19, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:01 UTC | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon stock | 3,999,998 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-000345 · ownership.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,881,823 F2 · kind: Also on December 28, 2023, following the TOI HC I Distribution, the General Partner, on behalf of Havencrest Healthcare Partners, L.P., made a further pro-rata in-kind distribution of the 3,999,998 shares Havencrest Healthcare Partners, L.P. received in the TOI HC I Distribution to Havencrest Healthcare Partners, L.P.'s limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 80,000 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 8,801,823 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. F3 · kind: (Continued from footnote 2) Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. F2 · price: Also on December 28, 2023, following the TOI HC I Distribution, the General Partner, on behalf of Havencrest Healthcare Partners, L.P., made a further pro-rata in-kind distribution of the 3,999,998 shares Havencrest Healthcare Partners, L.P. received in the TOI HC I Distribution to Havencrest Healthcare Partners, L.P.'s limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 80,000 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 8,801,823 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. F3 · price: (Continued from footnote 2) Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. F2 · ownership.nature: Also on December 28, 2023, following the TOI HC I Distribution, the General Partner, on behalf of Havencrest Healthcare Partners, L.P., made a further pro-rata in-kind distribution of the 3,999,998 shares Havencrest Healthcare Partners, L.P. received in the TOI HC I Distribution to Havencrest Healthcare Partners, L.P.'s limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 80,000 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 8,801,823 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. F3 · ownership.nature: (Continued from footnote 2) Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:01 UTC | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon stock | 4,561,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-000345 · ownership.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 12,801,821 F1 · kind: On December 28, 2023, TOI HC I, LLC distributed an aggregate of 4,561,050 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC I Distribution"). Immediately following the TOI HC I Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 3,999,998 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 8,801,823 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. F1 · price: On December 28, 2023, TOI HC I, LLC distributed an aggregate of 4,561,050 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC I Distribution"). Immediately following the TOI HC I Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 3,999,998 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 8,801,823 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. F1 · ownership.nature: On December 28, 2023, TOI HC I, LLC distributed an aggregate of 4,561,050 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC I Distribution"). Immediately following the TOI HC I Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 3,999,998 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 8,801,823 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 11, 2022 Filed Nov 16, 2022 02:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 365,321 | $2.33 | $851,197.93 |
DisclosureSEC source: 0000899243-22-035946 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,362,873 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.16 to $2.74, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 10, 2022 Filed Nov 11, 2022 02:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 61,281 | $2.98 | $182,617.38 |
DisclosureSEC source: 0000899243-22-035588 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,728,194 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.62 to $3.30, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 09, 2022 Filed Nov 11, 2022 02:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 80,000 | $3.09 | $247,200.00 |
DisclosureSEC source: 0000899243-22-035588 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,789,475 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.91 to $3.23, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 27,000 | $3.24 | $87,480.00 |
DisclosureSEC source: 0000899243-22-035588 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,869,475 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.06 to $3.38, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 02:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 19,167 | $3.28 | $62,867.76 |
DisclosureSEC source: 0000899243-22-035320 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,896,475 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.21 to $3.39, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 02:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 50,200 | $3.39 | $170,178.00 |
DisclosureSEC source: 0000899243-22-035320 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,915,642 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.57, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 02:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 45,500 | $3.58 | $162,890.00 |
DisclosureSEC source: 0000899243-22-035320 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,965,842 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.46 to $3.85, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 58,500 | $3.94 | $230,490.00 |
DisclosureSEC source: 0000899243-22-034844 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,011,342 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $4.17, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 50,272 | $4.26 | $214,158.72 |
DisclosureSEC source: 0000899243-22-034844 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,069,842 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.08 to $4.69, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 41,855 | $4.69 | $196,299.95 |
DisclosureSEC source: 0000899243-22-034844 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,120,114 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.83, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 28, 2022 Filed Oct 29, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 52,091 | $4.84 | $252,120.44 |
DisclosureSEC source: 0000899243-22-034501 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,161,969 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $5.03, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 27, 2022 Filed Oct 29, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 35,000 | $5.09 | $178,150.00 |
DisclosureSEC source: 0000899243-22-034501 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,214,060 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.95 to $5.16, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 26, 2022 Filed Oct 29, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 52,500 | $5.16 | $270,900.00 |
DisclosureSEC source: 0000899243-22-034501 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,249,060 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.94 to $5.30, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 25, 2022 Filed Oct 26, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 30,400 | $5.10 | $155,040.00 |
DisclosureSEC source: 0000899243-22-034156 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,301,560 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.34, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 29,400 | $4.98 | $146,412.00 |
DisclosureSEC source: 0000899243-22-034156 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,331,960 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $5.35, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 21, 2022 Filed Oct 26, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 20,000 | $4.96 | $99,200.00 |
DisclosureSEC source: 0000899243-22-034156 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,361,360 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $5.12, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 20, 2022 Filed Oct 21, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 12,000 | $4.83 | $57,960.00 |
DisclosureSEC source: 0000899243-22-033908 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,381,360 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.51 to $5.12, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 17,500 | $4.68 | $81,900.00 |
DisclosureSEC source: 0000899243-22-033908 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,393,360 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.82, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 18, 2022 Filed Oct 21, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 12,200 | $4.63 | $56,486.00 |
DisclosureSEC source: 0000899243-22-033908 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,410,860 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.44 to $4.92, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 8,249 | $4.60 | $37,945.40 |
DisclosureSEC source: 0000899243-22-033713 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,423,060 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.74, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 9,800 | $4.54 | $44,492.00 |
DisclosureSEC source: 0000899243-22-033713 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,431,309 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.22 to $4.77, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 13, 2022 Filed Oct 18, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 25,200 | $4.67 | $117,684.00 |
DisclosureSEC source: 0000899243-22-033713 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,441,109 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.77, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 14,343 | $4.70 | $67,412.10 |
DisclosureSEC source: 0000899243-22-033524 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,466,309 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.86, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any Security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 25,000 | $4.66 | $116,500.00 |
DisclosureSEC source: 0000899243-22-033524 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,480,652 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 to $4.85, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 21,500 | $4.33 | $93,095.00 |
DisclosureSEC source: 0000899243-22-033524 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,505,652 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.01 to $4.61, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 07, 2022 Filed Oct 8, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 14,652 | $4.63 | $67,838.76 |
DisclosureSEC source: 0000899243-22-033327 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,527,152 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.51 to $4.73, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 06, 2022 Filed Oct 8, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 33,509 | $4.45 | $149,115.05 |
DisclosureSEC source: 0000899243-22-033327 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,541,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.84, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 05, 2022 Filed Oct 8, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 14,060 | $4.78 | $67,206.80 |
DisclosureSEC source: 0000899243-22-033327 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,575,313 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.51 to $4.85, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 01:31 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 23,447 | $4.85 | $113,717.95 |
DisclosureSEC source: 0000899243-22-032851 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,589,373 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $5.05, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 01:31 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 16,765 | $4.72 | $79,130.80 |
DisclosureSEC source: 0000899243-22-032851 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,612,820 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.89, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:31 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 11,000 | $4.68 | $51,480.00 |
DisclosureSEC source: 0000899243-22-032851 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,629,585 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.78, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 21,000 | $4.62 | $97,020.00 |
DisclosureSEC source: 0000899243-22-032266 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,640,585 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.35 to $4.74, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 12,642 | $4.72 | $59,670.24 |
DisclosureSEC source: 0000899243-22-032266 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,661,585 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.49 to $4.85, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 27, 2022 Filed Sep 30, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 14,074 | $4.69 | $66,007.06 |
DisclosureSEC source: 0000899243-22-032266 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,674,227 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.84, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 26, 2022 Filed Sep 27, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 7,153 | $4.57 | $32,689.21 |
DisclosureSEC source: 0000899243-22-032050 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,688,301 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 to $4.78, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 5,375 | $4.19 | $22,521.25 |
DisclosureSEC source: 0000899243-22-032050 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,695,454 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.02 to $4.30, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 22, 2022 Filed Sep 27, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 13,086 | $4.25 | $55,615.50 |
DisclosureSEC source: 0000899243-22-032050 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,700,829 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.14 to $4.39, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 19,629 | $4.33 | $84,993.57 |
DisclosureSEC source: 0000899243-22-031553 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,713,915 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.01 to $4.51, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 200,000 | $4.50 | $900,000.00 |
DisclosureSEC source: 0000899243-22-031553 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,733,544 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.77, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.